Posters

    Association of urinary 11-dehydro-thromboxane B2 levels in smoking, smoking cessation and Tobacco Heating System use

    Gonzalez Zuloeta, A.; Pouly, S.; de La Bourdonnaye, G.; Baker, G.; Luedicke, F.

    Conference date
    Jun 27, 2014
    Conference name
    Society for Epidemiologic Research (SER) 2014
    Link to more information
    Topic
    Summary

    Smoking has been associated with cardiovascular disease and there is evidence that this might be mediated by the increased production of thromboxane. Whether metabolites of thromboxane, such as 11-dehydro-thromboxane B2 (TXB2), could be used as a biomarker of risk in the assessment of candidate modified risk tobacco products (MRTPS) is not clear. The aim of this literature review and meta-analysis (MA) was to determine the association of smoking status and TXB2 levels. Additionally we evaluated the effect of smoking cessation and the use of a tobacco heated system (THS) currently in development, to urinary levels of 11-dehydro-thromboxane B2. 

    Related Publications

    Comparison of Abdominal Aortic Aneurysm Growth in Adult Smoking Patients Who Either Switch to IQOS, Continue Smoking, or Quit Smoking

    Clinical

    Systematic review of the relation between smokeless tobacco and cancer of the pancreas in Europe and North America

    Clinical

    Reduced exposure to Harmful and Potentially Harmful Constituents after 90 days of use of Tobacco Heating System 2.2 Menthol in Japan: A comparison with continued cigarette use or smoking abstinence

    Clinical

    Reduced Exposure To Harmful And Potentially Harmful Constituents after 90 Days Of Use Of Tobacco Heating System 2.2 Menthol In Japan: A Comparison With Continued Cigarette Use Or Smoking Abstinence

    Clinical

    Psychometric Evaluation of the mCEQ applied to Cigarettes and Heat-Not-Burn Products in the US and Japan

    Clinical

    Pharmacokinetics Of Nicotine And Subjective Effects Following The Single Use Of A Non-Menthol And Menthol Version Of Tobacco Heating System 2.2 In Two Studies In Japan: A Comparison With Single Use Of A Combustible Cigarette And Nicotine Gum

    Clinical

    PMIScience.com is operated by Philip Morris International for the purpose of publishing and disseminating scientific information about Philip Morris International’s efforts in support of its smoke-free product portfolio. This site is a global site for use by scientists, the public health and regulatory communities, and other stakeholders with an interest in tobacco policy. The purpose of this site is not advertising or marketing, nor is it directed at any specific market. It is not intended for use by consumers. New tobacco products sold in the United States are subject to FDA regulation; therefore the content of this site is not intended to make, and nor should it be construed as making, any product related claims in the United States without proper FDA authorization. ​
    ​
    Reduced Risk Products ("RRPs”) is the term we use to refer to products that present, are likely to present, or have the potential to present less risk of harm to smokers who switch to these products versus continuing smoking. PMI has a range of RRPs in various stages of development, scientific assessment and commercialization. All of our RRPs are smoke-free products that deliver nicotine with far lower quantities of harmful and potentially harmful constituents than found in cigarette smoke.